Egle Therapeutics - About the company
Egle Therapeutics is a series A company based in Paris (France), founded in 2020 by Luc Boblet and Eliane Piaggio. It operates as a Provider of T cells based therapeutics for oncology and autoimmune diseases. Egle Therapeutics has raised $46.6M in funding from Life Sciences Partners and Bpifrance. The company has 3472 active competitors, including 1156 funded and 809 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Provider of T cells-based therapeutics for oncology and autoimmune disease. The company offers computational-based IL-2 modified variants and translational-based therapeutic Treg targets to restore the immune response.
- Website
- www.egle-tx.com/
- Email ID
- *****@egle-tx.com
- Phone Number
- +33 **********
Key Metrics
Founded Year
2020
Location
Paris, France
Stage
Series A
Total Funding
$46.6M in 2 rounds
Latest Funding Round
Investors
Ranked
383rd among 3472 active competitors
Employee Count
52 as on Aug 31, 2026
Sign up to download Egle Therapeutics' company profile
Egle Therapeutics's funding and investors
Egle Therapeutics has raised a total funding of $46.6M over 2 rounds. Its first funding round was on Oct 22, 2021. Its latest funding round was a Grant (prize money) round on Mar 17, 2025 for $*****. 1 investor participated in its latest round. Egle Therapeutics has 7 institutional investors.
Here is the list of recent funding rounds of Egle Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 17, 2025 | 9383793 | Grant (prize money) | 1801271 | 9430616 | 8519459 | 8525276 |
Oct 22, 2021 | 8643391 | Series A | 8837204 | 8791240 |
Access funding benchmarks and valuations. Sign up today!View details of Egle Therapeutics's funding rounds and investors
Egle Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Egle Therapeutics are Luc Boblet and Eliane Piaggio. Luc Boblet is the CEO of Egle Therapeutics.
Here are the details of Egle Therapeutics' key team members:
- Luc Boblet: Founder & CEO of Egle Therapeutics.
- Eliane Piaggio: Co-Founder of Egle Therapeutics. Contact Info: 1 email address
View details of Egle Therapeutics's Founder profiles and Board Members
Egle Therapeutics' employee count trend
Egle Therapeutics has 52 employees as of Aug 26. Here is Egle Therapeutics's employee count trend over the years:
Uncover Egle Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Egle Therapeutics's Competitors and alternates
Top competitors of Egle Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Egle Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
383rd |  Egle Therapeutics 2020, Paris (France), Series A | Provider of T cells based therapeutics for oncology and autoimmune diseases | $46.6M | 55/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Egle Therapeutics's competitors? Click here to see the top ones
Egle Therapeutics's Investments and acquisitions
Egle Therapeutics has made no investments or acquisitions yet.
Reports related to Egle Therapeutics
Here is the latest report on Egle Therapeutics's sector:
News related to Egle Therapeutics
Filter this listMedia has covered Egle Therapeutics for a total of 2 events in the last 1 year, 1 of them has been about company updates and 1 about people movement.
•
Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic DermatitisBusiness Wire•Dec 02, 2025•Egle Therapeutics
•
GENFIT Appoints Dr. Pejvack Motlagh as New Chief Medical OfficerBenzinga•Nov 27, 2025•Egle Therapeutics, Genfit
•
Egle Therapeutics secures €9.3M in French government funding for biotherapies.Business Wire•Mar 17, 2025•Egle Therapeutics, Carnot Curie Cancer, Takeda, Bpifrance
•
Egle Therapeutics names Christophe Quéva, Ph.D., its new CEO.Business Wire•Jan 13, 2025•Egle Therapeutics, Ovid Therapeutics
•
Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer MeetingBusiness Wire•Oct 25, 2024•Egle Therapeutics
•
•
Egle Therapeutics to share preclinical data for its first autoimmune disease program, EGL-003, with an oral presentation at the 2024 Promise of Interleukin-2 Therapy MeetingBusiness Wire•Jul 17, 2024•Egle Therapeutics
•
4Moving Biotech welcomes Luc Boblet as Chief Executive Officer to lead next phase of growthBusiness Wire•Jul 02, 2024•4Moving Biotech, Egle Therapeutics
•
•
Egle Therapeutics Strengthens its Leadership Team with the Appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical OfficerBusiness Wire•Mar 27, 2024•Egle Therapeutics, iCIMS
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Egle Therapeutics
Explore our recently published companies
- Una Home Care - Beverly Hills based, 2026 founded, Unfunded company
- Boooply - 2026 founded, Unfunded company
- Uaity - 2026 founded, Unfunded company
